CClinicalTrials.gg
CompletedNCT04885439Updated Apr 22, 2024

NextSteps Intervention for Advanced Cancer Patients and Caregivers

An interventional study of NextSteps in Lung Cancer and Gastrointestinal Cancer, sponsored by Baylor College of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Baylor College of Medicine · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 5 years 10 months after the study started (first participant enrolled Jul 2015, registered May 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study seeks to test the efficacy of a psychosocial intervention to empower advanced cancer patients and their caregivers and improve their quality of life (QOL). The program, called NextSTEPS, provides skills training in six domains that are central to patient and caregiver QOL: self-care, stress management, symptom management, effective communication, problem-solving, and social support.

Read the detailed description

In this study, 200 advanced cancer patients who are within one month of treatment initiation (baseline) and their caregivers will complete baseline surveys and be randomized to NextSTEPS or a usual medical care (UMC) condition. In addition to UMC, patients and caregivers in the NextSTEPS condition will each receive an intervention manual and six weekly 45-minute telephone counseling sessions with a trained interventionist. Patients and caregivers in both the NextSTEPS and UMC conditions will complete follow-up surveys at 8 weeks (primary endpoint), and 4 and 6 months post-baseline (secondary endpoints).

The specific aims are to:

  1. Determine the impact of NextSTEPS on patient physical and emotional QOL, palliative care utilization, and satisfaction with care relative to UMC. We hypothesize that at 8 weeks (2 months), and 4 and 6 months, patients in NextSTEPS will have less symptom burden, less emotional distress, greater palliative care utilization, and greater satisfaction with care relative to patients in UMC.
  2. Determine the impact of NextSTEPS on caregiver self-care, physical and emotional QOL, and satisfaction with care. We hypothesize that at 8 weeks, and 4 and 6 months, caregivers in NextSTEPS will report more self-care, better physical QOL, less emotional distress, and greater satisfaction with care relative to caregivers in UMC.

Secondary/exploratory aims and hypotheses are to:

Examine the effects of the NextSTEPS intervention on Self Determination Theory (SDT) constructs. We hypothesize that NextSTEPS will enhance patient and caregiver competence, autonomy, and relatedness.

Test whether the SDT constructs of competence, autonomy and relatedness mediate the effects of NextSTEPS on patient/caregiver outcomes as hypothesized.

Explore whether sociodemographic (e.g., age, gender), medical (e.g., disease stage, comorbidities), and relationship factors (e.g., whether the caregiver is a spouse/partner or other family member) moderate the effects of NextSTEPS on patient/caregiver competence, autonomy, and relatedness.

NextSTEPS fills an important service gap by providing education, skills training, and support to advanced cancer patients and their caregivers shortly after diagnosis. Home-based telephone delivery will facilitate dissemination and outreach. By empowering families with the skills they need to coordinate care and meet the challenges of advanced cancer together, NextSTEPS holds great promise for improving patient and caregiver QOL, and the quality of palliative and supportive care in cancer.

02

Conditions studied

  • Lung Cancer
  • Gastrointestinal Cancer
03

In context

Gastrointestinal Neoplasms

779 studies on the registry are indexed under Gastrointestinal Neoplasms; 231 are open to participants now.

This study's enrollment of 242 is above the median of 60 across 569 interventional studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 734 studies on the registry; 110 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 44 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Patient has stage 3A, 3B, or 4 NSLC or extensive stage SCLC and is within one month of treatment initiation OR patient has Stage 4 GI cancer and is within one month of treatment initiation
  2. patient is spending more than 50% of time out of bed on a daily basis as measured by an ECOG Performance Status rating of level 0, 1, or 2
  3. patient has stable brain metastases and no limitation on hepatic or renal function
  4. patient has a spouse/partner other or close family member who he/she defines as the primary caregiver
  5. patient and caregiver are age 18 years or older
  6. patient and caregiver have the ability to read and understand English at a sixth grade level, as determined by ability to understand the consent form
  7. patient and caregiver can provide informed consent

Exclusion criteria

Exclusion Criteria:

  1. patient or caregiver is deaf or has significant hearing impairment and thus cannot use the telephone
  2. patient is currently enrolled in hospice.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    NextSteps Intervention

    Patients and caregivers will each receive their own tailored manual and six weekly 45-minute telephone calls that correspond to the manual, delivered by a Masters level trained interventionist.

    Behavioral: NextSteps

  • No intervention
    Usual Medical Care

    UMC consists of standard oncologic care for the patient from the point of diagnosis of advanced cancer.

Interventions

  • BehavioralNextSteps

    Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.

06

What researchers measure

Primary outcomes

  1. Patient and Caregiver Depression

    Patient Reported Outcomes Measurement Information System Depression 6 item Short form

    Time frame: 2 months

  2. Patient and Caregiver Anxiety

    Patient Reported Outcomes Measurement Information System Anxiety 6 item Short form

    Time frame: 2 months

Secondary outcomes

  1. Patient and Caregiver Satisfaction with Care

    20-item Family Satisfaction with Care (FAMCARE) scale

    Time frame: 2 months, 4 months, and 6 months

  2. Patient Symptom Burden

    M D Anderson Symptom Inventory

    Time frame: 2 months, 4 months, and 6 months

  3. Patient and Caregiver Depression

    Patient Reported Outcomes Measurement Information System Depression 6 item Short form

    Time frame: 4 and 6 months

  4. Patient and Caregiver Anxiety

    Patient Reported Outcomes Measurement Information System Anxiety 6 item Short form

    Time frame: 4 and 6 months

07

Study locations

1 site
  • Baylor College of Medicine
    Houston, Texas 77030, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04885439
Lead sponsor
Baylor College of Medicine
Responsible party
Hoda Badr (Dr., Baylor College of Medicine) — Principal investigator
First posted
May 13, 2021
Start date
Jul 1, 2015
Primary completion
Dec 1, 2020
Completion
Jun 30, 2021
Last update
Apr 22, 2024

Study contacts

Hoda Badr, PhD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion